Ken Mills, Regenxbio CEO
Regenxbio gives glimpse at early Duchenne gene therapy results, plans pivotal study for accelerated approval
Regenxbio shared early biomarker results from a 12-year-old boy with Duchenne muscular dystrophy who received a higher dose of its gene therapy, and the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
